AU2010249015A1 - Treatment of MCI and Alzheimer's disease - Google Patents

Treatment of MCI and Alzheimer's disease Download PDF

Info

Publication number
AU2010249015A1
AU2010249015A1 AU2010249015A AU2010249015A AU2010249015A1 AU 2010249015 A1 AU2010249015 A1 AU 2010249015A1 AU 2010249015 A AU2010249015 A AU 2010249015A AU 2010249015 A AU2010249015 A AU 2010249015A AU 2010249015 A1 AU2010249015 A1 AU 2010249015A1
Authority
AU
Australia
Prior art keywords
nifedipine
nitroso
effective amount
therapeutically effective
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010249015A
Other languages
English (en)
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of AU2010249015A1 publication Critical patent/AU2010249015A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010249015A 2009-05-15 2010-05-13 Treatment of MCI and Alzheimer's disease Abandoned AU2010249015A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21645209P 2009-05-15 2009-05-15
US61/216,452 2009-05-15
US23455109P 2009-08-17 2009-08-17
US61/234,551 2009-08-17
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2010249015A1 true AU2010249015A1 (en) 2011-11-24

Family

ID=43069025

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010249015A Abandoned AU2010249015A1 (en) 2009-05-15 2010-05-13 Treatment of MCI and Alzheimer's disease

Country Status (7)

Country Link
US (1) US20100292281A1 (enExample)
EP (1) EP2429992A4 (enExample)
JP (1) JP2012526844A (enExample)
AU (1) AU2010249015A1 (enExample)
CA (1) CA2761298A1 (enExample)
MX (1) MX2011012015A (enExample)
WO (1) WO2010132671A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4991544B2 (ja) 2004-08-23 2012-08-01 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
WO2007041398A2 (en) 2005-09-30 2007-04-12 Vitae Pharmaceuticals, Inc. Treatment of cancer with specific rxr agonists
WO2012160563A2 (en) * 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20130040303A1 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for Alzheimer's Disease and/or Mild Cognitive Impairment, and Use Thereof
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
KR20150027800A (ko) * 2012-06-15 2015-03-12 고에키 자이단 호징 센탄 이료 신코 자이단 경도 인지 장해의 예방 및/또는 치료제
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR102651292B1 (ko) 2015-10-31 2024-03-25 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
DK3426302T3 (da) 2016-03-10 2023-02-27 Io Therapeutics Inc Behandling af autoimmunsygdomme med kombinationer af rxr-agonister og skjoldbruskkirtelhormoner
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
MX2020003223A (es) * 2017-09-20 2020-09-21 Io Therapeutics Inc Tratamiento de enfermedades con ésteres de agonistas de rxr selectivos.
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
CA2325353A1 (en) * 1998-04-08 1999-10-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
AU2004292966A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
US20080107601A1 (en) * 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
ES2374716T3 (es) * 2005-04-15 2012-02-21 Research & Innovation S.P.A. Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
WO2007064010A1 (ja) * 2005-12-02 2007-06-07 Mochida Pharmaceutical Co., Ltd. アルツハイマー型認知症予防・治療剤
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
EP2018186A2 (en) * 2006-04-11 2009-01-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Ｉｃａｍ−１発現抑制剤

Also Published As

Publication number Publication date
WO2010132671A1 (en) 2010-11-18
MX2011012015A (es) 2012-04-30
EP2429992A4 (en) 2012-11-28
US20100292281A1 (en) 2010-11-18
EP2429992A1 (en) 2012-03-21
JP2012526844A (ja) 2012-11-01
CA2761298A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
US20100292281A1 (en) Treatment of mci and alzheimer's disease
JP2012526844A5 (enExample)
AU2010353287A1 (en) Treatment of MCI and Alzheimer's disease
Das et al. A close look at BACE1 inhibitors for Alzheimer’s disease treatment
Pohanka Alzheimer s disease and oxidative stress: a review
Fernandez‐Perez et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
EP3560496A1 (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
CA3005887A1 (en) Methods for treating alzheimer's disease and related disorders
US20220054454A1 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
WO2011050095A2 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
KR20110066623A (ko) Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
Lovell et al. Treatment of MCI and Alzheimer's Disease
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
CA2568213A1 (en) Composition and method for the treatment of tauopathies
ES2449594T3 (es) Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
Samentar et al. A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
CA2368850C (en) Methods for the prevention and/or the treatment of glutamate cytotoxicity
WO2013020909A1 (en) Materials and methods for the treatment of tauopathies
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application